Phadebas® Amylase Test
Quantifying alpha-amylase
The Phadebas® Amylase Test is used for both qualitative and quantitative assessment of the alpha-Amylase enzyme. The active component of Phadebas is DSM-P, microspheres in which a blue dye has been chemically bound. Alpha‑Amylase degrades the microspheres, thereby releasing the blue dye. Enzymatic activity of the tested sample is given by measuring the absorbance of the blue solution. Phadebas is used in a wide range of applications from diagnosis of pancreatitis to quality control tests for food & beverages and as a method for detecting saliva in forensic investigations. For the forensic labs, Phadebas is also available with the DSM-P reagent immobilised on filter paper, Phadebas Forensic. In 2010 Magle launched a new product in the Phadebas family, Phadebas Honey Diastase test. All Phadebas products are marketed and sold world wide in Magle's own name or through distributors. For additional information, please visit www.phadebas.com
Arista®
Absorbable hemostat for surgical use
Arista® is approved for surgical use by the FDA, European authorities, Japanese FDA and the Chinese health authorities for in-vivo use to achieve hemostasis. The product is marketed by Magle's premium partner Medafor,Inc (www.medafor.com). Magle has developed and now produces the active component of Arista, viz DSM-A. The DSM-A microspheres are applied directly on the blood source where they act as hydrophilic molecular sieves. DSM-A thus accelerates natural hemostasis by concentrating blood platelets, proteins and red blood cells, forming a gel matrix around the particles. The resorption process begins immediately and the microspheres are fully degraded into glucose within 2 days.
For additional information, please contact us at info@magle.se
Spherex®
Trans-arterial chemoembolisation for the treatment of primary hepatocellular carcinoma
Spherex® is registered as a medical device in Japan, where it is marketed by Pfizer's business partner Yakult Honsha. The active component, DSM-S microspheres, is produced by Magle and in Spherex the microspheres are sterilised and suspended in saline solution. DSM-S is administered via a catheter into the hepatic artery where it forms an occlusion in the vessel tree. Co-administered with a cytostatic drug, it helps to achieve markedly higher local levels of the drug and to much less side effects due to reduced systemic circulation. Magle has acquired all rights to the product and trademark Spherex outside of Japan, and CE marked the product for the European market.
Debrisan®
Wound dressing containing polysaccharide beads (not yet available)
Debrisan® was once a successful product for wound management, marketed by Pharmacia. Magle has purchased the trademark from Pharmacia, with the intention of developing a new platform of innovative products for advanced wound healing. Originally focused on hard-to-heal wounds, we have now extended our interest to include wounds where negative pressure is used as a tool, where Magle's formulation lends itself very well. Debrisan is currently not available commercially. Since 2008, we have invested much time and effort in acquiring fundamental knowledge about the wound healing processes and learning how DSM may bring innovation to the market. We now have a great platform that we feel facilitates healthy product development initiatives. Debrisan will be launched when we have secured that our products bring substantial and clinically verified value to patients.
